March 1, 2018 12:00 AM EST
Financing

Suck­ing up tal­ent out of No­var­tis, a boom­ing Ru­bius adds an­oth­er $100 mil­lion mega-round to the kit­ty

John Carroll

Editor & Founder

Just 8 months af­ter putting the fin­ish­ing touch­es to a $120 mil­lion round, Flag­ship start­up Ru­bius Ther­a­peu­tics is back at the mon­ey well, draw­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times